Biotechs hold gold, silver and bronze in the 2018 IPO market. Cancer immunotherapy devloper ARMO BioSciences (ARMO) is by far the year's best-performing IPO, up 200% from its offer price. Rounding out the podium is chronic itch biotech...read more
Two small deals are on the calendar for the holiday week ahead, including single-asset Reg A+ IPO Aspen REIT and blank check company Crescent Funding. We expect IPO filing activity to pick up as we move...read more
Menlo Therapeutics, which is developing treatments for moderate to severe skin itch and chronic cough, raised $119 million by offering 7 million shares at $17, the high end of the range of $16 to $17. Menlo Therapeutics plans to list on the Nasdaq under the...read more
Big biotech swings: 2016 IPO AveXis pops 82%, 2018 IPO Menlo drops 77%
• ...read more
Biotechs take the podium with the year's 3 best IPOs
Biotechs hold gold, silver and bronze in the 2018 IPO market. Cancer immunotherapy devloper ARMO BioSciences (ARMO) is by far the year's best-performing IPO, up 200% from its offer price. Rounding out the podium is chronic itch biotech...read more
US IPO Week Ahead: Look for a wave of filings in a quiet holiday week with 2 IPOs
Two small deals are on the calendar for the holiday week ahead, including single-asset Reg A+ IPO Aspen REIT and blank check company Crescent Funding. We expect IPO filing activity to pick up as we move...read more
Anti-itch biotech Menlo Therapeutics prices IPO at $17, the high end of the range
Menlo Therapeutics, which is developing treatments for moderate to severe skin itch and chronic cough, raised $119 million by offering 7 million shares at $17, the high end of the range of $16 to $17. Menlo Therapeutics plans to list on the Nasdaq under the...read more